These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 12372943)

  • 41. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
    Hori K; Onoyama K; Iseki K; Fujimi S; Fujishima M
    Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Erythropoietin-induced changes in protein nutrition: quantitative assessment by urea kinetic modeling analysis.
    Canaud B; Bouloux C; Rivory JP; Taib J; Garred LJ; Florence P; Mion C
    Blood Purif; 1990; 8(5):301-8. PubMed ID: 2091690
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ultrapure dialysate reduces dose of recombinant human erythropoietin.
    Schiffl H; Lang SM; Bergner A
    Nephron; 1999; 83(3):278-9. PubMed ID: 10529639
    [No Abstract]   [Full Text] [Related]  

  • 44. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states.
    Thamer M; Richard C; Ray NF; Greer JW; Cotter DJ; Pearson BC
    Am J Kidney Dis; 1996 Aug; 28(2):235-49. PubMed ID: 8768919
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients.
    Gejyo F; Saito A; Akizawa T; Akiba T; Sakai T; Suzuki M; Nishi S; Tsubakihara Y; Hirakata H; Bessho M;
    Ther Apher Dial; 2004 Dec; 8(6):443-59. PubMed ID: 15663544
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
    Lui SF; Law CB; Ting SM; Li P; Lai KN
    Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency.
    Locatelli F; Olivares J; Walker R; Wilkie M; Jenkins B; Dewey C; Gray SJ;
    Kidney Int; 2001 Aug; 60(2):741-7. PubMed ID: 11473657
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial.
    Beiraghdar F; Panahi Y; Einollahi B; Nemati E; Ghadiani MH; Sahebkar A; Maghsoudi N; Marzony ET
    Clin Lab; 2012; 58(7-8):737-45. PubMed ID: 22997974
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
    Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
    ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters.
    Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
    Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Increased in vitro and ex vivo proliferation of erythroid precursors induced by calcitriol in chronic renal failure. Synergistic effect with rHuEPO].
    Aucella F; Gatta G; Vigilante M; Scalzulli RP; Mantuano S; Carotenuto M; Stallone C
    G Ital Nefrol; 2002; 19(2):137-42. PubMed ID: 12195411
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
    Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
    Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of hemodialysis and recombinant human erythropoietin on determinants of blood viscosity.
    Shand BI; Buttimore AL; Lynn KL; Bailey RR; Robson RA
    Ren Fail; 1994; 16(3):407-13. PubMed ID: 8059023
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of using ultrapure dialysate for hemodialysis on the level of circulating bacterial fragment in renal failure patients.
    Kwan BC; Chow KM; Ma TK; Cheng PM; Leung CB; Li PK; Szeto CC
    Nephron Clin Pract; 2013; 123(3-4):246-53. PubMed ID: 24008429
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of recombinant human erythropoietin therapy on plasma endothelin-1 levels during hemodialysis.
    Stefanidis I; Mertens PR; Wurth P; Bach R; Makropoulos W; Mann H; Heintz B
    Int J Artif Organs; 2001 Jun; 24(6):367-73. PubMed ID: 11482502
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients.
    Abu-Alfa AK; Cruz D; Perazella MA; Mahnensmith RL; Simon D; Bia MJ
    Am J Kidney Dis; 2000 Jun; 35(6):1076-82. PubMed ID: 10845820
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: proposal for a hematocrit most beneficial to hemodynamics.
    Tagawa H; Nagano M; Saito H; Umezu M; Yamakado M
    Clin Nephrol; 1991 Jan; 35(1):35-8. PubMed ID: 2007294
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Combined therapy with L-carnitine and erythropoietin of anemia in chronic kidney failure patients undergoing hemodialysis].
    Wanic-Kossowska M; Kazmierski M; Pawliczak E; Kobelski M
    Pol Arch Med Wewn; 2007; 117(1-2):14-9. PubMed ID: 17642201
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure.
    Qureshi IZ; Abid K; Ambreen F; Qureshi AL
    Saudi Med J; 2007 Feb; 28(2):193-6. PubMed ID: 17268695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.